Mission Bio Launches Single-Cell Multi-Omics Assay to Support Cancer Drug Development
Friday, June 06, 2025
Mission Bio has introduced a new single-cell multi-omics solution designed to improve clinical outcomes in cancer drug development.
The company’s latest innovation, the Single-Cell Genotype and Targeted Gene Expression assay, enhances its Tapestri Platform by enabling the simultaneous analysis of genotype and targeted gene expression in over 10,000 individual cells.
This marks the first commercially available tool of its kind and is aimed at supporting pharmaceutical companies in Phase II and III trials by helping identify patients most likely to benefit from treatment.
The assay is offered through Mission Bio's Pharma Assay Development (PAD) services, providing tailored support across assay design, development, data interpretation, and assay transfer. It has been developed to address three key areas: understanding resistance to therapy, advancing T-cell therapy design, and improving patient selection strategies in oncology trials.
Traditional methods in oncology drug development often struggle to capture tumour heterogeneity and mechanisms of resistance due to limitations in separate or fragmented approaches. By integrating genomic and gene expression data from the same cell, the upgraded Tapestri Platform offers a high-resolution view of tumour behaviour and treatment response. This helps pharmaceutical researchers gain deeper insights that may reduce the risk of failure during late-stage clinical development.
The solution also includes sample multiplexing capabilities, which help lower the cost of single-cell analysis by around 60% compared to using multiple platforms. Previous users of the Tapestri Platform have already demonstrated the benefits of combining gene expression with single-cell genotyping, such as tracing resistant subclones in acute myeloid leukaemia under drug pressure.
Looking ahead, Mission Bio plans to further enhance the assay by adding immunophenotyping, offering a broader multi-omics perspective to support drug development in precision oncology.
Source: businesswire.com
